Maxiflo 250 Rotacaps contain a combination of Formoterol (6mcg) and Fluticasone Propionate (250mcg), indicated for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). Formoterol is a long-acting beta2-adrenergic receptor agonist that provides bronchodilation by relaxing airway smooth muscle, thereby improving airflow and reducing symptoms such as wheezing and shortness of breath. Fluticasone Propionate is a corticosteroid with potent anti-inflammatory properties that decreases airway inflammation, reduces mucus production, and prevents exacerbations. The synergistic effect of these two agents helps in controlling persistent respiratory symptoms and improving lung function. Maxiflo 250 Rotacaps are administered via a rotahaler device, delivering the medication directly to the lungs for rapid onset and sustained action. It is recommended for patients requiring both bronchodilation and anti-inflammatory therapy, particularly those inadequately controlled on corticosteroids alone. Common side effects may include oral candidiasis, throat irritation, and tremors. Patients should rinse their mouth after inhalation to minimize local adverse effects. Maxiflo 250 Rotacaps should be used regularly as prescribed and not for acute bronchospasm relief. Caution is advised in patients with cardiovascular disorders, and therapy should be adjusted based on clinical response.